

CLINUVEL

ASX ANNOUNCEMENT

Melbourne, Australia, 27 March 2026

ASX: CUV | Börse Frankfurt: UR9 | ADR Level I: CLVLY

CLINUVEL's global programs showcased at America's largest dermatology conference

Vitiligo, including new proprietary AI tool, and EPP feature at the 2026 AAD Meeting in Denver

EXECUTIVE SUMMARY

- 20,000 dermatology professionals expected to attend AAD Annual Meeting in Denver
- CLINUVEL's melanocortin programs feature across AAD 2026: developing and delivering novel treatments for patients with vitiligo and erythropoietic protoporphyria (EPP)
- Proprietary Vitiligo Visual Algorithm (VVA) AI tool unveiled
- Pavilion of Photomedicine reimagined for 2026 to engage audiences, differentiate CLINUVEL
- Satellite symposia provide real-time program feedback

CLINUVEL today revealed its expansive program for the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver from 27–31 March. The Company's work features heavily across academic presentations, exhibitions and events, with a focus on the development of afamelanotide to treat vitiligo and SCENESSE® (afamelanotide), the only FDA-approved treatment for patients with the rare disorder erythropoietic protoporphyria (EPP).¹

"Following the success of the 2025 AAD Meeting, our team has refined its approach to ensure maximum engagement with the dermatology community ultimately aimed at helping to treat patients with melanocortin therapies," said Dr Linda Teng, CLINUVEL's Head of North American Operations. "We know there is great demand from physicians who wish to offer more to their vitiligo patients, while interest in our commercial program for EPP continues to grow as patients seek approved therapy.

"We are particularly excited to be unveiling the Vitiligo Visual Algorithm (VVA), a tool being developed entirely in-house that leverages artificial intelligence (AI) to objectively evaluate clinical images. With the VVA we seek to establish a new gold standard in vitiligo clinical assessments to help drive physician decision making."

Vitiligo Visual Algorithm (VVA) – AI driven assessment

Following extensive feedback from vitiligo experts involved in its programs, CLINUVEL started developing the novel, AI-driven VVA tool in 2025 with the intention of setting a new standard in clinical evaluation and analysis. Customising existing AI visual algorithms, CLINUVEL's in-house development team has built the VVA to objectively assess pigmentation using standardised clinical photographs, tracking an individual patient's treatment progress over time.

CLINUVEL has chosen to use the AAD to seek feedback from the dermatology community on the VVA, which continues to be trained. The Company is currently using the VVA alongside its ongoing CUV105 vitiligo study, with plans to include the tool in the protocol of its upcoming CUV107 Phase III study.

Pavilion of Photomedicine

Launched in 2025, CLINUVEL's Pavilion of Photomedicine has been completely reimagined for the 2026 AAD Meeting to take attendees on an immersive journey through CLINUVEL's scientific heritage, patient focus and future vision. The 4,000 square foot Pavilion is designed to differentiate CLINUVEL's approach to drug development and patient care through an enclosed environment dedicated to the stories of patients, academic engagement and CLINUVEL's development heritage.



Above: an artist's impression of CLINUVEL's Pavilion of Photomedicine at the 2026 AAD Annual Meeting.

Satellite Symposia

Results from CLINUVEL's programs were presented and discussed at three satellite symposia on 26 March: the Photodermatology Society 35th Annual Meeting, the Global Vitiligo Foundation (GVF) Annual Symposium, and the Skin of Color Society (SOCS) Scientific Symposium. The Company has supported all three of these expert meetings as part of its ongoing commitment to academic engagement.

"The feedback from satellite symposia is invaluable to our teams as we can see our programs and data discussed in real-time by the real experts in the field," Dr Teng said. "This gives us the opportunity to refine our approaches as well as anticipate potential issues before they occur."

AAD 2026

The AAD represents a network of over 20,000 dermatology professionals. Its Annual Meeting is the largest dermatology congress in North America, attracting dermatologists, researchers, and industry professionals from all over the world.

– END –

¹ SCENESSE® is currently only approved for EPP. Please refer to the prescribing information on <http://scenesse.com> for risk and safety information.

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL I: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL's lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

<https://www.clinuvel.com/investors/contact-us>

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "foresee," "intend," "likely," "may," "objective," "potential," "plan," "predict," "project," "seek," "should," "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran's Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2025 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Contact:

Tel: +61 3 9660 4900

Fax: +61 3 9660 4909

Email: mail@clinuvel.com

Australia (Head Office), Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia

